Cipher Pharmaceuticals Maintains Solid Q2 Performance

Cipher Pharmaceuticals (TSE:CPH) has released an update.

Cipher Pharmaceuticals has sustained its financial performance in Q2 2024 with an adjusted EBITDA of $3.1 million, on par with the previous year, and reported increased sales for its Epuris product line. Additionally, the company has completed a significant acquisition of Natroba, aiming to expand its dermatology and infectious disease portfolio in North America and beyond.

For further insights into TSE:CPH stock, check out TipRanks’ Stock Analysis page.